reference/33082816

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/33082816

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	6561
issn	1949-2553
issueIdentifier	5
pageRange	6550-6561
publicationName	Oncotarget
startingPage	6550
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_0af585b4e4572d71a2484156e749bf47 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_8762af291d69cf5348b3c4749e5a8182 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_168fecb54099f664e2135d67c5d2d339
bibliographicCitation	Sahoo D, Wei W, Auman H, Hurtado-Coll A, Carroll PR, Fazli L, Gleave ME, Lin DW, Nelson PS, Simko J, Thompson IM, Leach RJ, Troyer DA, True LD, McKenney JK, Feng Z, Brooks JD. Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. Oncotarget. 2018 Jan 19;9(5):6550–61. PMID: 29464091; PMCID: PMC5814231.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f1385ad61f7bb5cdc6052c7fe1669974 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d08bf03834d16555394b5f04e90c569f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f51620f52af69ceab1689e8be39c5457 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9bce9ab7b86a0d7f0864bf954f1cc2ef http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_62bf5da76050aee810f81217fea49eff http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0afbadaaf5661ccc0c2e273ed41fc295 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bd1643f0db81d6423a5b8cf21df942da http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db6a5215ed97dc1c9a78bd201c91389c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_79e07034484781dc8b6e93465ce794e5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0cee0b543434fd92f9b950470942b889 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_60970449f1c62beea7b56f7f42339831 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db5ab8b84b44d90812c3df7b2c582901 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c76b8f56a3c9db49e380e9562e95da54 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f8503e1fbf599dd58d01d42e396fa2f7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_953cd3d852624df01e57dd89a13e6ab6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a889ef0e8077f0955abd6835137bb92 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_00377b32873df9281e76418b52323f15
date	2018-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC5814231 https://pubmed.ncbi.nlm.nih.gov/29464091 https://doi.org/10.18632/oncotarget.23973
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/37803 https://portal.issn.org/resource/ISSN/1949-2553
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fce276cc0efd2412c7dafdbb1e82fcc8 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5995 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.4.21.77 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_80a26383e00e892c98ebd598edcc5dbb http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6678 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_6fab6bf193c862d5cac8dd80e83ceb7a

Total number of triples: 47.